Company intelligence / Profile preview

PTS International

Ownership: Private
Development stage: Other

Overview

Para-Toluenesulfonamide injection developed by PTS International has been approved in China for the treatment of non-small cell lung cancer. The company sponsored both a completed Phase III trial for airway obstruction in NSCLC and an earlier withdrawn Phase I study in solid tumors. No additional active programs are listed.

Therapeutic areas: Rare DiseasesOncology
Modalities: Small molecule
Industry: Biotech

Partnerships

Gongwin Biopharm Holdings Co., Ltd.

Beyond the preview

Go deeper on PTS International.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PTS International.

Explore the full profile